Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial

被引：0
|
作者：
Dodick, D. [1 ]
Nahas, S. [2 ]
Pozo-Rosich, P. [3 ,4 ]
Bilchik, T. [5 ]
McAllister, P. [6 ]
Finnegan, M. [7 ]
Ma, J. [7 ]
Chalermpalanupap, T. [7 ]
Dabruzzo, B. [7 ]
Lipton, R. [8 ]
机构：
[1] Mayo Clin, Scottsdale, AZ USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Autonomous Univ Barcelona, Barcelona, Spain
[5] Yale Sch Med, New Haven, CT USA
[6] New England Inst Neurol & Headache, Stamford, CT USA
[7] AbbVie, Madison, NJ USA
[8] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2022年 / 23卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P110
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine
    Yang, Chun-Pai
    Lee, Chia-Fang
    Dell'Agnello, Grazia
    Hundemer, Hans-Peter
    Lipsius, Sarah
    Wang, Shuu-Jiun
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (10) : 1653 - 1666
  • [42] Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period
    Weiden, Peter J.
    Du, Yangchun
    Liu, Chih-Chin
    Stanford, Arielle D.
    CNS SPECTRUMS, 2019, 24 (04) : 419 - 425
  • [43] Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
    Kivitz, Alan
    Sedova, Liliana
    Churchill, Melvin
    Vizcaya, Cynthia
    Sutariya, Reema
    Cao, Wenhao
    Singhal, Atul
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4750 - 4752
  • [44] Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patients
    Vermeire, S.
    Danese, S.
    Hebuterne, X.
    D'Haens, G.
    Takeuchi, K.
    Finney-Hayward, T.
    Klaff, J.
    Holweg, C. T. J.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I8 - I9
  • [45] Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 158 - 158
  • [46] Effects of atogepant as evaluated by the activity impairment in migraine-diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-week, double-blind, randomized phase 3 (ADVANCE) trial for preventive treatment of migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    HEADACHE, 2021, 61 : 46 - 47
  • [47] Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 106 - 106
  • [48] Efficacy of Fremanezumab by Prior Number of Preventive Treatments With Inadequate Response in Patients With Episodic Migraine and Chronic Migraine: Results of the International, Multicenter Phase 3b
    Pazdera, L.
    Cohen, J. M.
    Ning, X.
    Ramirez-Campos, V
    Yang, R.
    HEADACHE, 2020, 60 : 13 - 14
  • [49] History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release
    Pae, Chi-Un
    Masand, Prakash S.
    Marks, David M.
    Krulewicz, Stan
    Han, Changsu
    Peindl, Kathleen
    Mannelli, Paolo
    Patkar, Ashwin A.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2009, 10 (04): : 435 - 441
  • [50] Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release
    Han, C.
    Masand, P. S.
    Krulewicz, S.
    Peindl, K.
    Mannelli, P.
    Varia, I. M.
    Pae, C. -U.
    Patkar, A. A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2009, 34 (01) : 79 - 88
12345